BD's PharMingen buy to help "speed" conversion of research products to clinical use, firm tells analysts.
This article was originally published in The Gray Sheet
Executive SummaryBD/PHARMINGEN COMBINATION TO ACCELERATE CONVERSION OF RESEARCH use reagents to clinical products by capitalizing on Becton Dickinson's expertise in developing products for clinical use and PharMingen's experience in the research market, Deborah Neff, president of BD Immunocytometry Systems, told analysts April 24 in New York City.
You may also be interested in...
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.